Screener
Sarepta Therapeutics, Inc. SRPT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
FAQ
- What is Sarepta Therapeutics, Inc.'s cash & equivalents?
- Sarepta Therapeutics, Inc. (SRPT) reported cash & equivalents of $571.15M in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Sarepta Therapeutics, Inc.'s cash & equivalents increased by 11.9% year-over-year, from $510.6M to $571.15M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s cash & equivalents has grown at a -11.8% compound annual growth rate (CAGR), from $1.5B to $801.28M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Sarepta Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude